Zusammenfassung
In der adjuvanten Chemotherapie des Kolonkarzinoms im Stadium III sollte bei Patienten bis 70 Jahre die Gabe von infusionalem Fluorouracil (5-FU) oder oralem Capecitabin in Kombination mit Oxaliplatin Standard sein. Ein neuer Standard für die palliative Therapie des Her2/neu-positiven fortgeschrittenen Magenkarzinoms und des Karzinoms des gastroösophagealen Übergangs ist die Behandlung mit Trastuzumab in Kombination mit einer Chemotherapie. Patienten mit Hochrisiko-Weichteilsarkomen profitieren neben der chirurgischen Resektion und Nachbestrahlung von einer neoadjuvanten Chemotherapie in Kombination mit regionaler Tiefenhyperthermie. Für Patienten mit Bronchialkarzinom steht nach der EGFR-Mutationsanalyse ein weiterer personalisierter Therapieansatz kurz vor der Routineanwendung: Neben dem EGFR-Mutationsstatus sollen vor allem Nie-Raucher zukünftig auch auf eine Aberration im ALK-Gen untersucht werden.
Abstract
In patients up to 70 years of age with colon carcinoma stage III adjuvant chemotherapy with infusions of fluorouracil (5-FU) or oral capecitabine combined with oxaliplatin should be the standard method. A new standard for the palliative treatment of Her2/newly positive advanced gastric cancer and cancer at the gastro-esophageal junction is the administration of trastuzumab combined with chemotherapy. Patients with high-risk soft tissue sarcoma can be helped, in addition to surgical resection and subsequent radiotherapy, by neoadjuvant chemotherapy combined with regional deep hyperthermia. For patients with lung cancer additional individualized treatment is about to become routine. In addition to the EGFR mutation status, all non-smokers should in future be tested for aberration in the anaplastic lymphoma kinase (ALK) gene.
Schlüsselwörter
Kolonkarzinom - Magenkarzinom - Sarkome - Bronchialkarzinom - Chemotherapie
Keywords
colon carcinoma - gastric cancer - sarcoma - bronchial carcinoma - chemotherapy
Literatur
-
1
Albert S R, Sargent D J, Smyrk T C. et al .
Adjuvant mFOLFOX
with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts)
with resected stage III colon cancer (CC): Results from NCCTG Intergroup
Phase III Trial N0147.
J Clin Oncol.
2010;
28
18s (suppl; abstr CRA3507)
-
2
André T, Boni C, Navarro M. et al .
Improved overall survival with oxaliplatin,
fluorouracil, and leucovorin as adjuvant treatment in stage II or
III colon cancer in the MOSAIC trial.
J Clin Oncol.
2009;
27
3109-16
-
3
Bang Y J, Van Cutsem E. et al .
Trastuzumab
in combination with chemotherapy versus chemotherapy alone for treatment
of HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet.
2010;
376
687-697
-
4
Haller D, Taberno J, Maroun J. et
al .
First efficacy findings from a randomized phase
III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV
for stage III colon cancer (NO16968/XELOXA study).
Eur
J Cancer .
2009;
7 (Suppl. 3)
4
-
5
Issels R D, Lindner L H, Verweij J. et al .
Neo-adjuvant chemotherapy alone or with
regional hyperthermia for localized high-risk soft-tissue sarcoma:
a randomized phase 3 multicentre study.
Lancet Oncol.
2010;
11
561-570
-
6
Kang Y, Ohtsu A, Van Cutsem E. et al .
AVAGAST: A randomized, double-blind, placebo-controlled,
phase III study of first-line capecitabine and cisplatin plus bevacizumab
or placebo in patients with advanced gastric cancer (AGC).
J
Clin Oncol.
2010;
28 (Suppl.)
18s (Abstract LBA4007)
-
7
Kuebler J P, Wieand H S, O’Connell M J. et al .
Oxaliplatin combined
with weekly bolus fluorouracil and leucovorin as surgical adjuvant
chemotherapy for stage II and III colon cancer: results from NSABP
C-07.
J Clin Oncol.
2007;
25
2198-204
-
8
Kwak E L, Bang Y J, Camidge D R. et al .
Anaplastic lymphoma kinase
inhibition in non-small-cell lung cancer.
N Engl J Med.
2010;
363
1693-703
-
9
McCleary J, Meyerhardt J, Green E. et al, The ACCENT Collaborative Group .
Impact
of older age on the efficacy of newer adjuvant therapies in > 12,500
patients (pts) with stage II/III colon cancer: Findings
from the ACCENT Database.
J Clin Oncol.
2009;
27 (Suppl.)
15s (Abstract 4010)
-
10
Pao W, Miller V, Zakowski M. et
al .
EGF receptor gene mutations are common in lung
cancers from „never smokers” and are associated
with sensitivity of tumors to gefitinib and erlotinib.
Proc
Natl Acad Sci USA.
2004;
101
13 306
-
11
Rosell R, Moran T, Queralt B S. et al .
Screening for Epidermal Growth Factor Receptor
Mutations in Lung Cancer.
N Engl J Med.
2009;
361
958-967
-
12
Schmiegel W, Pox C, Adler G. et
al .
S3-Guidelines Conference „Colorectal Carcinoma” 2004.
Z Gastroenterol.
2004;
42
1129-1177
-
13
Schmiegel W, Reinacher-Schick A, Arnold D. et al .
Update S3-guideline „colorectal
cancer” 2008.
Z Gastroenterol.
2008;
46
799-840
-
14
Twelves C, Wong A, Nowacki M P. et al .
Capecitabine as adjuvant treatment for
stage III colon cancer.
N Engl J Med.
2005;
352
2696-2704
-
15
Wendtner C M, Abdel-Rahman S, Krych M. et al .
Response to neoadjuvant chemotherapy combined
with regional hyperthermia predicts long-term survival for adult
patients with retroperitoneal and visceral high-risk soft tissue
sarcomas.
J Clin Oncol.
2002;
20
3156-3164
-
16
Wolmark N, Yothers G, OŽConnell J M. et al .
A phase III trial comparing
mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma
of the colon: Results of NSABP Protocol C-08.
J Clin Oncol.
2009;
27 (Suppl.)
18s;
(Abstract LBA4)
-
17
Schmiegel W, Pox C, Arnold R, Porschen R, Rödel C, Reinacher-Schick A.
Colorectal
carcinoma: the management of polyps, (neo)adjuvant therapy, and
the treatment of metastases.
Dtsch Arztebl Int.
2009;
106
843-848
Prof. Dr. C.-M. Wendtner
Klinik I für Innere Medizin
Klinikum
der Universität zu Köln
Kerpener Straße
62
50937 Köln
eMail: Clemens.Wendtner@uni-koeln.de
